Vortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin receptors and inhibits the reuptake of serotonin. More specifically, vortioxetine acts via the following biological mechanisms: as a serotonin reuptake inhibitor (SRI) through inhibition of the serotonin transporter, as a partial agonist of the 5-HT1B receptor, an agonist of 5-HT1A, and an antagonist of the 5-HT3, 5-HT1D, and 5-HT7 receptors. SMSs were developed because there are many different subtypes of serotonin receptors, however, not all of these receptors appear to be involved in the antidepressant effects of SRIs. Some serotonin receptors seem to play a relatively neutral or insignificant role in the regulation of mood, but others, such as 5-HT1A autoreceptors and 5-HT7 receptors, appear to play an oppositional role in the efficacy of SRIs in treating depression.
用于治疗重度抑郁症成人患者。
The Johns Hopkins Hospital, Baltimore, Maryland, United States
National Hepatology and Tropical Research Institute, Cairo, Egypt
University of Naples Federico II, Napoli, Italia, Italy
Takeda Selected Site, Tokyo, Japan
Mental Health Institute & Faculty of Psychiatry of The Second Xiangya Hospital, Central South University, Changsha, Hunan, China
The First Affiliated Hospital of Chongqing Medical University, Chongqing, Province, China
Department of Psychiatry, First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China
Cliantha Research Limited, Ahmedabad, Gujarat, India
Cliantha Research Limited, Ahmedabad, Gujarat, India
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.